The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1 Approval is based on interim data from ongoin...
To help protect access to medicines for cancer and rare disease patients, AstraZeneca has filed a legal challenge to critical aspects of the drug pri...
With a dual-headed probe, the Vscan Air SL offers a sector array and a linear array on a single device which is ideal for switching between focused cardi...
Boston Scientific Corporation (NYSE: BSX) announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed F...
PD-L1 IHC 22C3 pharmDx, Code SK006, is indicated as an aid in identifying certain cancer patients for treatment with KEYTRUDA® (pembrolizumab), Merck&r...
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) f...
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), announced that its IoNovo Iodine product has been gr...
Abrysvo is administered as a single dose injection into the muscle. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals...
– Enrolled Patients May Continue Receiving Study Medicine – – Studies in Solid Tumors Unaffected – The FDA action follows the pre...
DE refers to the exemption of medical devices intended for marketing from regulatory requirements, allowing clinical trials to be conducted on such devices...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
Complete Integrity Implant System is now fully cleared; targeting launch in Q1-2024 Integrity is highly differentiated by its knitted structure, resulting...
This patent is expected to expire no earlier than June 2035. The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating sclero...
© 2025 Biopharma Boardroom. All Rights Reserved.
